IRB#9902  Nivolumab or Nivolumab + Ipilimumab in Advanced or Metastatic Solid Tumors

IRB#19388 A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

IRB# 21194 study A phase 1 study of SGN-CD228A in select advanced solid tumors

IRB# 21508 Study of ORIC-101 in Combination With Anticancer Therapy

IRB# 21464 A Study of mRNA-2752 for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade

IRB# 21766 A Phase I/II study of GEN-001 in Combination with Avelumab in Patients with Advanced Solid Tumors Who Have Progressed during or after Treatment with Anti-PD-(L)1 therapy

IRB# 21797 A Phase 1b Dose Escalation Study to evaluate GS-3583, a FLT3 agonist Fc fusion protein, in Subjects with Advanced Solid Tumors

IRB# 22082 A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors

IRB# 22760 Study of Magrolimab in Participants With Solid Tumors

IRB# 23157 Study of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

IRB# 23236 Study of SGN-STNV in Advanced Solid Tumors

IRB# 24483 Phase 1 study of BAL0981 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors

IRB# 24406 A PHASE 1 STUDY OF KSQ-4279 ALONE AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS

IRB# 24635 Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)

IRB# 24649 An open-label, master protocol to study Datopotamab Deruxtecan (Dato-DXd) alone and in combination with anticancer agents in patients with advanced/metastatic solid tumors

8/10/2022

http://www.ohsu.edu/research/rda/so/knight.php
Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view.

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB 21548</td>
<td>Fusion-NTRK (previously treated)</td>
</tr>
<tr>
<td>IRB 21810</td>
<td>RET Mutations</td>
</tr>
<tr>
<td>IRB 17674</td>
<td>Loxo-195 in fusion-NTRK (previously treated) solid tumors</td>
</tr>
<tr>
<td>IRB 16676</td>
<td>BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors</td>
</tr>
<tr>
<td>IRB 18164</td>
<td>A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity</td>
</tr>
</tbody>
</table>

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

8/10/2022

http://www.ohsu.edu/research/rda/so/knight.php
No known mutation, phase 1; TREM1 expression phase 2

Locally-advanced or metastatic solid tumor with an NRG1 gene fusion

Advanced solid tumor that has progressed after all available standard therapy or for which standard therapy has proven to be ineffective, or if no further standard therapy exists

Solid tumors with a BRAF fusion alteration

Solid tumors with a MYC gene mutation

IRB 22223
A Phase 1a/1b Open-Label Study to Evaluate PY159 as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

IRB 22580 CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

IRB 22902
A PHASE 2, SUBPROTOCOL OF DAY101 MONOTHERAPY FOR PATIENTS WITH RECURRENT, PROGRESSIVE, OR REFRACTORY SOLID TUMORS WITH ACTIVATING BRAF GENE FUSION

IRB 21998
A Phase 1/2 Open-label study to evaluate PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

IRB 20197
A Study of PY314 in Subjects With Advanced Solid Tumors

Microsatellite Stable (MSS) colorectal, ovarian, and endometrial

TREM2 expression phase 2

IRB 22863
A Study of PY314 in Subjects With Advanced Solid Tumors

IRB 22925
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors

IRB 22926
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors

IRB 22862
An open-label study to evaluate VIP152 (BAY 1251152) alone or in combination with pembrolizumab in subjects with advanced cancer

IRB 22864
A Study of 23ME-00610 in Patients With Advanced Solid Malignancies